This report provides exclusive insights into the COVID-19 impact on the Ulcerative Colitis Market. The detailed analysis provides information about the impact of the outbreak on the demand and supply conditions, trends and forecasts of the Ulcerative Colitis Market. Moreover, the impact analysis covers the study of the COVID-19 on the supply chain of Ulcerative Colitis Market. The sectoral impact shall provide insights into both short term and long term effects of the pandemic on the related and support industries.
A recent report published by Infinium Global Research on
ulcerative colitis market provides an in-depth analysis of segments and
sub-segments in the global as well as regional ulcerative colitis market. The
study also highlights the impact of drivers, restraints, and macro indicators
on the global and regional ulcerative colitis market over the short term as
well as long term. The report is a comprehensive presentation of trends,
forecast and dollar values of global ulcerative colitis market. According to
the report, the global ulcerative colitis market is projected to grow at a healthy
CAGR over the forecast period of 2019-2025.
Market Insight
According to the CDC (Centers for Disease Control), the worldwide
incidence of ulcerative colitis is between 0.5 to 24.5 cases per 100,000
persons per year. The recurrence of the disease’s symptoms is also high.
Recently, numerous medical treatments for ulcerative colitis have developed.
5-aminosalicylic acids (5-ASAs), corticosteroids, thiopurine, calcineurin
inhibitors, and anti-tumor necrosis factor (TNF) treatments are recent medical
treatments. Furthermore, golimumab, vedolizumab, AJM300, tofacitinib are some
upcoming treatments. Budesonide foam will be used as one treatment option in
patients with distal colitis. Herbal medicine is also effective for active UC.
In the near future, physicians will able to use many different treatments for
UC patients.
The rising incidence of ulcerative colitis disease across the globe is the major driving factor for the ulcerative colitis market.
Furthermore, factors such as advancements in the healthcare industry in the
past few years, the arrival of enhanced drugs, and increasing research
explorations to develop an innovative treatment for ulcerative colitis are
other driving factors for the growth of the market. Increasing demand for
better treatment procedures along with developing healthcare infrastructures is
fueling the ulcerative colitis market growth. However, stringent government
regulations towards approval of biosimilars restrain the market growth. Moreover,
unmet needs in the treatment of ulcerative colitis are expected to provide
lucrative growth opportunities for the ulcerative colitis market.
Geographically, North America dominates the global ulcerative
colitis market owing to the presence of key players and the growing prevalence
of the disease in the region. The continuing funding for the development of new
therapeutics for the treatment of the condition also drives the market growth
in North America. Asia-Pacific is the second-largest market for ulcerative
colitis due to expanding incidences of ulcerative colitis accompanied by the
expansion of the drug development sector in this region. Ulcerative colitis is
increasing in several parts of Asia with gender distribution and age of
diagnosis.

Segment Covered
The report on global ulcerative colitis market covers segments
such as drug type and disease type. On the basis of drug type, the sub-markets
include anti-inflammatory drugs, anti-TNF biologics, immunosuppressant,
calcineurin inhibitors, and other drug types. On the basis of disease type, the
sub-markets include ulcerative proctitis, proctosigmoiditis, left-sided
colitis, pancolitis or universal colitis, and fulminant colitis.
Companies Profiled:
The report provides profiles of the companies in the market such
as GlaxoSmithKline plc, Eli Lilly and Company, Johnson & Johnson, Sanofi
Aventis A/S, AstraZeneca plc, Abbott Laboratories, Merck & Co., Inc., InDex
Pharmaceuticals Holding AB, Ajinomoto Pharmaceuticals Co., Ltd., Avaxia
Biologics Inc., and other companies.
Report Highlights:
The report provides deep insights into the demand forecasts,
market trends, and micro and macro indicators. In addition, this report
provides insights into the factors that are driving and restraining the growth
in this market. Moreover, The IGR-Growth Matrix analysis given in the report
brings an insight into the investment areas that existing or new market players
can consider. The report provides insights into the market using analytical
tools such as Porter's five forces analysis and DRO analysis of ulcerative
colitis market. Moreover, the study highlights current market trends and
provides forecast from 2019-2025. We also have highlighted future trends in the
market that will affect the demand during the forecast period. Moreover, the
competitive analysis given in each regional market brings an insight into the
market share of the leading players.